Genetic and pharmaceutical inactivation of LMP7 or LMP10 subunits is sufficient to elicit profound impacts on both ventricular hypertrophy and atrial fibrillation induced by Ang II infusion (Li et al., 2018, 2019; Xie et al., 2019, 2020). This evidence concerns the gene PSMB8 and cardiac hypertrophy.